160 related articles for article (PubMed ID: 14717935)
1. Podocyte injury associated glomerulopathies induced by pamidronate.
Barri YM; Munshi NC; Sukumalchantra S; Abulezz SR; Bonsib SM; Wallach J; Walker PD
Kidney Int; 2004 Feb; 65(2):634-41. PubMed ID: 14717935
[TBL] [Abstract][Full Text] [Related]
2. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
Markowitz GS; Appel GB; Fine PL; Fenves AZ; Loon NR; Jagannath S; Kuhn JA; Dratch AD; D'Agati VD
J Am Soc Nephrol; 2001 Jun; 12(6):1164-1172. PubMed ID: 11373339
[TBL] [Abstract][Full Text] [Related]
3. Pamidronate-induced kidney injury in a patient with metastatic breast cancer.
Nagahama M; Sica DA
Am J Med Sci; 2009 Sep; 338(3):225-8. PubMed ID: 19581797
[TBL] [Abstract][Full Text] [Related]
4. Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient.
Kunin M; Kopolovic J; Avigdor A; Holtzman EJ
Nephrol Dial Transplant; 2004 Mar; 19(3):723-6. PubMed ID: 14767032
[No Abstract] [Full Text] [Related]
5. [Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review].
Jotterand V; Moll S; Martin PY; Saudan P
Nephrol Ther; 2009 Apr; 5(2):134-8. PubMed ID: 19013118
[TBL] [Abstract][Full Text] [Related]
6. Proliferating cells in HIV and pamidronate-associated collapsing focal segmental glomerulosclerosis are parietal epithelial cells.
Dijkman HB; Weening JJ; Smeets B; Verrijp KC; van Kuppevelt TH; Assmann KK; Steenbergen EJ; Wetzels JF
Kidney Int; 2006 Jul; 70(2):338-44. PubMed ID: 16761013
[TBL] [Abstract][Full Text] [Related]
7. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature.
Jia N; Cormack FC; Xie B; Shiue Z; Najafian B; Gralow JR
BMC Cancer; 2015 Jul; 15():535. PubMed ID: 26197890
[TBL] [Abstract][Full Text] [Related]
8. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?
Sauter M; Jülg B; Porubsky S; Cohen C; Fischereder M; Sitter T; Schlondorff D; Gröne HJ
Am J Kidney Dis; 2006 Jun; 47(6):1075-80. PubMed ID: 16731304
[No Abstract] [Full Text] [Related]
9. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.
Desikan R; Veksler Y; Raza S; Stokes B; Sabir T; Li ZJ; Jagannath S
Br J Haematol; 2002 Nov; 119(2):496-9. PubMed ID: 12406092
[TBL] [Abstract][Full Text] [Related]
10. Nephrotic syndrome and renal failure in a patient with metastatic breast cancer.
Yoshizawa H; Akimoto T; Nishino K; Inoue M; Ito C; Takeda S; Kotoda A; Tamba K; Yumura W; Muto S; Ueda Y; Kusano E
Clin Exp Nephrol; 2011 Aug; 15(4):567-71. PubMed ID: 21416249
[TBL] [Abstract][Full Text] [Related]
11. C1q nephropathy: a variant of focal segmental glomerulosclerosis.
Markowitz GS; Schwimmer JA; Stokes MB; Nasr S; Seigle RL; Valeri AM; D'Agati VD
Kidney Int; 2003 Oct; 64(4):1232-40. PubMed ID: 12969141
[TBL] [Abstract][Full Text] [Related]
12. Reversibility of pamidronate-associated glomerulosclerosis.
Shreedhara M; Fenves AZ; Benavides D; Stone MJ
Proc (Bayl Univ Med Cent); 2007 Jul; 20(3):249-53. PubMed ID: 17637879
[TBL] [Abstract][Full Text] [Related]
13. A case of recurrent focal segmental glomerulosclerosis after kidney transplantation associated with variant conversion in the Columbia classification.
Unagami K; Kawanishi K; Shimizu T; Kanzawa T; Toki D; Okumi M; Omoto K; Horita S; Koike J; Honda K; Nagashima Y; Ishida H; Tanabe K; Nitta K
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():96-100. PubMed ID: 26031598
[TBL] [Abstract][Full Text] [Related]
14. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
[TBL] [Abstract][Full Text] [Related]
15. Modulation of podocyte phenotype in collapsing glomerulopathies.
Barisoni L; Kopp JB
Microsc Res Tech; 2002 May; 57(4):254-62. PubMed ID: 12012394
[TBL] [Abstract][Full Text] [Related]
16. Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis.
Markowitz GS; Nasr SH; Stokes MB; D'Agati VD
Clin J Am Soc Nephrol; 2010 Apr; 5(4):607-15. PubMed ID: 20203164
[TBL] [Abstract][Full Text] [Related]
17. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum.
Stokes MB; Markowitz GS; Lin J; Valeri AM; D'Agati VD
Kidney Int; 2004 May; 65(5):1690-702. PubMed ID: 15086908
[TBL] [Abstract][Full Text] [Related]
18. Podocyte and endothelial injury in focal segmental glomerulosclerosis: an ultrastructural analysis.
Taneda S; Honda K; Ohno M; Uchida K; Nitta K; Oda H
Virchows Arch; 2015 Oct; 467(4):449-58. PubMed ID: 26266776
[TBL] [Abstract][Full Text] [Related]
19. Toxic acute tubular necrosis following treatment with zoledronate (Zometa).
Markowitz GS; Fine PL; Stack JI; Kunis CL; Radhakrishnan J; Palecki W; Park J; Nasr SH; Hoh S; Siegel DS; D'Agati VD
Kidney Int; 2003 Jul; 64(1):281-9. PubMed ID: 12787420
[TBL] [Abstract][Full Text] [Related]
20. Focal and segmental glomerulosclerosis and porteinuria associated with unilateral renal agenesis.
Kiprov DD; Colvin RB; McCluskey RT
Lab Invest; 1982 Mar; 46(3):275-81. PubMed ID: 7062725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
